Press Releases
CHARLOTTE, N.C., Feb. 9, 2026 /PRNewswire/ -- Columbus McKinnon Corporation (Nasdaq: CMCO) ("Columbus McKinnon" or the "Company"), a leading designer, manufacturer and marketer of intelligent motion solutions for material handling, today announced financial results for its fiscal year 2026 third quarter, which ended December 31, 2025.
Third Quarter 2026... (continue reading...)
ALISO VIEJO, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced the closing of its initial public offering of 10,781,250 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 1,406,250 additional shares of its common stock, at a public offering price of $16.00 per share. The aggregate gross proceeds from the offering... (continue reading...)
MIAMI, Feb. 09, 2026 (GLOBE NEWSWIRE) -- PennantPark Investment Corporation (NYSE: PNNT) (the "Company") announced today financial results for the first quarter ended December 31, 2025.
HIGHLIGHTS Quarter ended December 31, 2025 (unaudited)($ in millions, except per share amounts)
Assets and Liabilities: Investment portfolio (1)$1,218.5 Net assets$457.2 Net asset value per share$7.00 Quarterly change in net asset value per share (1.5)% Credit... (continue reading...)VANCOUVER, Wash.--(BUSINESS WIRE)-- ZoomInfo, (NASDAQ: GTM) the Go-To-Market Intelligence Platform, today announced its financial results for the fourth quarter and full-year ended December 31, 2025.
“In 2025 we delivered record revenue, expanded profitability, and increased free cash flow, while building the all-in-one AI platform for go-to-market teams,” said Henry Schuck, ZoomInfo Founder and CEO. “In 2026, our focus is on bringing that platform to our... (continue reading...)
- FDA issues Complete Response Letter for RGX-121 (clemidsogene lanparvovec) for treatment of Mucopolysaccharidosis II (MPS II)
- REGENXBIO plans to work with FDA on a path forward with the goal of resubmitting the BLA
ROCKVILLE, Md., Feb. 9, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for RGX-121 (clemidsogene... (continue reading...)
More Press Releases
View Older Stories-
PennantPark Floating Rate Capital Ltd. Announces Financial Results for the First Quarter Ended December 31, 2025
-
Resideo To Participate at Upcoming Investor Conferences
-
Azenta Life Sciences and Frontier Space Announce Strategic Partnership to Advance Space-Based Life Sciences Research Infrastructure
-
Ichor Holdings, Ltd. Announces Fourth Quarter and Fiscal Year 2025 Financial Results
-
Fox Factory Announces Strategic Board Refresh
-
Cincinnati Financial Reports Fourth-Quarter and Full-Year 2025 Results
-
Frontier Group Holdings, Inc. Announces New Board Member
-
Allison Transmission Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call
-
Chegg Reports 2025 Fourth Quarter and Full Year Financial Results
-
Quantum to Announce Fiscal Third Quarter 2026 Financial Results on February 17, 2026
-
AECOM reports first quarter fiscal 2026 results
-
SL Green Realty Corp. to Participate in Citi’s 31st Annual Global Property CEO Conference
-
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results
-
Credo Provides Preliminary Third Quarter Fiscal Year 2026 Revenue Results, Updated Revenue Guidance for Fourth Quarter of Fiscal Year 2026 and Schedules Third Quarter Fiscal Year 2026 Financial Result
-
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
-
Tredegar Appoints David Parks to Board of Directors
-
nLIGHT, Inc. Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Freshpet, Inc. Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
DigitalOcean Announces Date of Fourth Quarter 2025 Earnings Conference Call
-
Duff & Phelps Utility and Infrastructure Fund Inc. Discloses Sources of Distribution – Section 19(a) Notice
-
Cipher Mining Announces Date of Fourth Quarter and Full Year 2025 Business Update Conference Call
-
Parsons Secures $91 Million Contract Extension for U.S. Diplomatic Mission Security Worldwide
-
TWFG, Inc. To Announce Fourth Quarter 2025 Financial Results On Wednesday, February 25, 2026
-
American Coastal Insurance Corporation Schedules Fourth Quarter and Full Year 2025 Financial Results and Conference Call
-
Gladstone Investment Corporation Announces Notes Offering
-
Mobile Infrastructure Announces Timing of Fourth Quarter and Full Year 2025 Earnings Release and Conference Call
-
Magnite to Participate in the Susquehanna 15th Annual Technology Conference
-
Dakota Gold Announces Offering of Common Stock
-
ACM Research to Release Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026
-
Agomab Announces Closing of Initial Public Offering
-
CEA Industries Appoints Accounting and Compliance Expert Glenn W. Tyranski to Its Board of Directors
-
Flowserve to Participate in Upcoming Investor Conferences
-
McLaughlin & Stern Expands to San Francisco with Addition of Dillingham & Murphy Team
-
BRIXMOR PROPERTY GROUP REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS
-
Amkor Technology Reports Financial Results for the Fourth Quarter and Full Year 2025
-
Travel Guard® launches sweepstakes to send fan to the 2026 Zurich Classic of New Orleans
-
Upwork Reports Fourth Quarter and Full Year 2025 Financial Results
-
In HelloNation, Auto Repair Expert Shawn Books of Waukesha, WI, Shares What to Do When the Check Engine Light Comes On
-
SEC Chairman Atkins is Making Funds More Affordable Here's How We Can Build on His Plan
-
The Manitowoc Company Reports Fourth-Quarter and Full-Year 2025 Financial Results; Provides Full-Year 2026 Guidance
-
EVI Industries Reports Record Second Quarter Results
-
For The Record Introduces Editable Speech-to-Text in FTR RealTime
-
H&R Block Combines AI Power with Digital Enhancements and Unmatched Tax Pro Expertise to Win Tax Season 2026
-
PrairieSky Announces Dividend Increase and 2025 Annual and Fourth Quarter Results
-
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
-
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings
-
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
CSX Announces $670M Locomotive Fleet Upgrade with Wabtec
-
374Water Appoints Stephen H. McKnight to Board of Directors
-
Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

